Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial

PURPOSE: In the HER2CLIMB study, patients with human epidermal growth factor receptor 2 (HER2)–positive breast cancer with brain metastases (BMs) showed statistically significant improvement in progression-free survival (PFS) with tucatinib. We describe exploratory analyses of intracranial efficacy...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Clin Oncol
Auteurs principaux: Lin, Nancy U., Borges, Virginia, Anders, Carey, Murthy, Rashmi K., Paplomata, Elisavet, Hamilton, Erika, Hurvitz, Sara, Loi, Sherene, Okines, Alicia, Abramson, Vandana, Bedard, Philippe L., Oliveira, Mafalda, Mueller, Volkmar, Zelnak, Amelia, DiGiovanna, Michael P., Bachelot, Thomas, Chien, A. Jo, O’Regan, Ruth, Wardley, Andrew, Conlin, Alison, Cameron, David, Carey, Lisa, Curigliano, Giuseppe, Gelmon, Karen, Loibl, Sibylle, Mayor, JoAl, McGoldrick, Suzanne, An, Xuebei, Winer, Eric P.
Format: Artigo
Langue:Inglês
Publié: American Society of Clinical Oncology 2020
Sujets:
RAPID COMMUNICATIONS
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7403000/
https://ncbi.nlm.nih.gov/pubmed/32468955
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.00775
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires